Migraine Excellence Hub

In interim INFUSE data, ≥50% of adults with prior anti-CGRP preventive failure reported cognitive symptom improvement after eptinezumab.

Post hoc subgroup analysis of interim phase 3 data shows weight loss with atogepant in migraine and overweight or obesity.

Physicians managing chronic migraine may be interested in new comparative patient-reported data from the FORWARD study, which evaluated treatment satisfaction with onabotulinumtoxinA versus topiramate. In...

At the 2026 American Academy of Neurology Annual Meeting in Chicago, IL, investigators presented real-world evidence evaluating whether glucagon-like peptide-1 receptor agonists influence healthcare...